Project assistant: Formulation development of novel tuberculosis compounds into long acting injectables at SDU in Odense

Opportunity summary

A two-year position within pharmaceutical sciences focusing on formulation development and biopharmaceutical understanding of the performance of novel compounds for the treatment of tuberculosis is available at the Department of Physics, Chemistry, and Pharmacy in the pharmacy research group. Starting date: 01 October 2026, or as soon as possible thereafter. Application deadline: 31 August 2026 Project background Long-acting injectables (LAIs) are pharmaceutical products intended for weekly, monthly or with an even lower administration frequency, which provides a continued drug release and thereby a steady exposure of the delivered compound. LAIs are typically administered intramuscularly (IM) or subcutaneously (SC) as oil solutions, in situ forming gels, microspheres, implants, micro- or nanosuspensions, with focus on suspensions in the present work. For individuals suffering of tuberculosis LAIs can provide a huge benefit in disease treatment, due to the long duration time the disease requires. LAIs have, with huge clinical success, been applied in the treatment of antipsychotic conditions and the area contains some of the most successful LAI formulations seen from a therapeutic perspective. In the 1960s, oil-based parenteral depot formulations, containing antipsychotics, were introduced in the clinical practice1 …

This is a shortened extract from the public vacancy. Follow the original posting for the complete and authoritative description.